Navigation Links
Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES)
Date:7/18/2013

critical role in the protection and overall health of the ocular surface. Mucins are essential for lubrication; the removal of allergens, pathogens, and debris; and corneal epithelial healing to reduce ocular surface damage.  In addition, MIM-D3 may have additional benefits than currently available dry eye therapies including the potential to improve neural function, which may improve corneal sensitivity and integrity.7  

Phase 2 study results for MIM-D3 demonstrated that the use of MIM-D3, dosed twice a day, results in consistent improvements across multiple dry eye signs and symptoms with no safety or tolerability issues.  A Phase 3 study is scheduled to begin before the end of 2013, which will be conducted by Ora, Inc.

"Bausch + Lomb is committed to delivering effective ophthalmic therapeutic solutions for eye care professionals and their patients, and dry eye represents a significant unmet need," said Cal Roberts, M.D., chief medical officer, Bausch + Lomb. "Given the promising results of the Phase 2 studies, we are excited about the potential  of giving eye care professionals a new choice for treating one of the most common and bothersome eye conditions."

If approved, the new technology would dramatically expand Bausch + Lomb's ability to compete in a $2.5 billion global dry eye market growing at 10 percent annually,8 while creating an opportunity to explore expanded ophthalmic applications.

"Bausch + Lomb and Mimetogen share a commitment to developing new and effective therapies that address unmet medical needs," said Garth Cumberlidge, Ph.D., president and chief executive officer, Mimetogen Pharmaceuticals. "We are thrilled to be working with such a respected partner as Bausch + Lomb. The company's commitment to innovation, expertise and resources, combined with its global reach and powerful
'/>"/>

SOURCE Bausch + Lomb
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bausch + Lomb distribuirá lentes trifocais difractivas e intraoculares tóricas da PhysIOL nos principais mercados asiáticos, europeus e do oriente médio
2. Leica Microsystems and Bausch + Lomb Sign Global Agreement for Surgical Operating Microscopes
3. Bausch + Lomb soumet une déclaration denregistrement pour un projet doffre publique initiale
4. Bausch + Lomb Files Registration Statement For Proposed Initial Public Offering
5. Bausch + Lomb ernennt Robert Bertolini zum Präsident und Chief Financial Officer
6. Bausch + Lomb designa a Robert Bertolini presidente y CFO
7. Bausch + Lomb nomme Robert Bertolini président et directeur financier
8. Bausch + Lomb Names Robert Bertolini President And Chief Financial Officer
9. Bausch + Lomb und CROMA spenden dringend benötigte Augentropfen
10. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
11. Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... With the NCAA set to undergo ... an interview with Yale University Associate Athletic Director Steve ... approach to ensuring student-athlete experience that is consistent with ... a number of key factors that contribute to a ... factor in creating this culture seems simple at first. ...
(Date:8/31/2014)... tea reduces non-cardiovascular mortality by 24%, reveals a study ... by Professor Nicolas Danchin from France. , Professor Danchin ... coffee it,s probably better to drink tea. Coffee and ... Their effects on cardiovascular (CV) health have been investigated ... the effects of coffee and tea on CV mortality ...
(Date:8/30/2014)... Barcelona, Spain Sunday 31 August 2014: A ... and safe in a real world setting, according ... by Dr Stylianos Pyxaras from Germany. The direct ... features that improve operator control and has the ... outcomes in patients with severe aortic stenosis. , ...
(Date:8/30/2014)... 31, 2014 Not only is USHEALTH Advisors ... has just recorded its highest level of late-summer sales, including ... company is going to set a new record in 2014,” ... “Our growth in both weekly annualized volume and the ... last week of August, we saw even more of our ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, ... a best-seller within golf and tennis. Golfers and tennis players ... most by using the compression elbow sleeve to help treat ... condition that causes pain on the inner side of your ... the bony bump on the inside of your elbow. The ...
Breaking Medicine News(10 mins):Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2
... are less likely to develop high blood pressure say researchers ... the study researchers analyzed data from two large studies, which ... women questionnaires, which asked about their folate and supplemental folic ... at the start of the study. It was found that ...
... suggest people who carry a gene that produces a ... small increased risk for stroke.// ,Researchers reviewed medical ... found that previous study results were observational in nature. ... confounding factors by looking at data on the link ...
... a recent study researchers have linked breathing cancer-causing compounds ... cancer among offspring. They also believe that nearly all ... mother’s inhalation of noxious substances. ,The study compared ... and younger who died from leukemia and other cancers ...
... Men who receive a common therapy after prostate cancer surgery ... based on // findings of a recent study. For ... therapy suffered a broken bone within five years of diagnosis, ... receive the treatment. ,Androgen-deprivation therapy has traditionally been given ...
... Several studies have linked the use of estrogen replacement therapy ... mineral density( BMD ) is known as a good indicator ... men to determine how BMD related to the risk of ... decline at the beginning of the study. Researchers then measured ...
... Previous studies have shown inhaled corticosteroids can reduce the ... However, results from a study conducted by researchers from ... more than 2,650 patients with COPD who were prescribed ... 90-day period. Nearly 5,400 patients who had never used ...
Cached Medicine News:
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Red Lens Maddox...
Maddox Rod, short handle (12cm)...
Medicine Products: